Anti-CBLB/RNF56 Polyclonal Antibody from ProteoGenix; catalogue ARO-A22212; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Anti-CBLB/RNF56 Polyclonal Antibody: Enhancing Immune Response and Fighting Cancer
The Anti-CBLB/RNF56 Polyclonal Antibody is a powerful tool for researchers in the biotech industry. This antibody specifically targets the CBLB/RNF56 protein, which plays a crucial role in regulating immune response and has been linked to various types of cancer.
The CBLB/RNF56 protein is a key player in the immune system, acting as a negative regulator of T-cell activation. This means that it helps to control the strength and duration of immune responses, preventing overactivation and potential autoimmune diseases. However, in certain cancers, this protein is overexpressed, leading to suppression of the immune response and allowing cancer cells to evade detection and destruction. The Anti-CBLB/RNF56 Polyclonal Antibody binds to this protein, blocking its function and boosting the immune response against cancer cells.
The Anti-CBLB/RNF56 Polyclonal Antibody has a wide range of applications in both basic research and drug development. Its ability to enhance immune response makes it a valuable tool for studying immune-related diseases, such as autoimmune disorders and cancer. Additionally, this antibody can be used in drug screening and target validation studies, as well as in the development of immunotherapies for cancer treatment.
The Anti-CBLB/RNF56 Polyclonal Antibody has been extensively tested and validated in various experimental models. In a recent study, researchers used this antibody to investigate the role of CBLB/RNF56 in the development of melanoma. They found that targeting this protein with the antibody resulted in increased T-cell activation and reduced tumor growth, highlighting its potential as a therapeutic target for cancer treatment.
In another study, the Anti-CBLB/RNF56 Polyclonal Antibody was used to study the effect of CBLB/RNF56 on the immune response in a mouse model of autoimmune diabetes. The results showed that blocking this protein with the antibody led to a decrease in disease severity, providing further evidence of its role in regulating immune response.
This Anti-CBLB/RNF56 Polyclonal Antibody is a highly specific and reliable tool for studying the function of the CBLB/RNF56 protein. Its ability to enhance immune response and its potential as a therapeutic target for cancer make it a valuable asset for researchers in the biotech industry. With its proven effectiveness in multiple experimental models, this antibody is a must-have for any study involving CBLB/RNF56.
In summary, the Anti-CBLB/RNF56 Polyclonal Antibody is a powerful tool for studying immune response and cancer. Its biological function, main applications, and experimental use cases make it a valuable asset for researchers in the biotech industry. Don’t miss out on the opportunity to enhance your research with this highly specific and reliable antibody. Order now and take a step towards advancing your research goals.
ProteoGenix catalogue number ARO-A22212. For research use only.
Target: E3 ubiquitin-protein ligase CBL-B, EC:2.3.2.27, Casitas B-lineage lymphoma proto-oncogene b, RING finger protein 56, RING-type E3 ubiquitin transferase CBL-B, SH3-binding protein CBL-B, Signal transduction protein CBL-B, CBLB, RNF56; Clonality: Polyclonal Antibody; Applications: ELISA, IHC.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | IHC |
|---|---|---|---|---|---|---|---|---|---|
| E3 ubiquitin-protein ligase CBL-B, EC |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
